<?xml version="1.0" encoding="UTF-8"?>
<article article-type="research-article" xml:lang="en" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher">london-journal-of-medical-and-health-research</journal-id>
<journal-title-group>
<journal-title>London Journal of Medical and Health Research</journal-title>
</journal-title-group>
<issn publication-format="print">2515-5784</issn>
<issn publication-format="electronic">2515-5792</issn>
<publisher><publisher-name>JournalsPress</publisher-name></publisher>
<self-uri xlink:href="https://journalspress.com/journal-seo-export/jats/64605.xml" />
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">64605</article-id>
<title-group>
<article-title>Pyruvate Potential Effects on Covid-19 Virus Infection: Novel Fluid Intervention and Prevention</article-title>
</title-group>
<volume>20</volume>
<issue>6</issue>
<fpage>69</fpage>
<lpage>78</lpage>
<abstract><p>Numerous experimental studies demonstrated that Pyruvate is more beneficial than anions in current fluids due to its beneficial biological and pharmacological properties via increasing hypoxia/anoxia tolerance, correcting hypoxic lactic acidosis and exerting anti-oxidative stress, which target against major features of pathological defects in Covid-19 viral infection: hypoxia and cytokine storm. These characteristics indicate that pyruvate is robustly systemic metabolism and multiorgan function protective in critical care patients with or without Covid-19 viral infection. Albeit it is not an anti-virus agent, studies suggest that pyruvate potentially facilitate anti-virus drugs, cytokine IL-6 blockers and interferons against Covid-19 and even inhibit virus replication as chloroquine treated Covid-19. Despite of not FDA-approved, many pyruvate clinical studies with several hundred patients subjected to various diseases strongly support its clinical effectiveness and safety. Currently, pyruvate is a nutritional supplement in markets. It is proposed in this review that compassionate uses of pyruvate-enriched intravenous and oral rehydration solutions are encouraged in intervention and prophylaxis of Covid-19 viral infection.</p></abstract>
<self-uri content-type="pdf" xlink:href="http://journalspress.com/LJMHR_Volume20/1430_Pyruvate-Potential-Effects-on-Covid-19-Virus-Infection-Novel-Fluid-Intervention-and-Prevention.pdf?" />
<self-uri content-type="html" xlink:href="https://journalspress.com/pyruvate-potential-effects-on-covid-19-virus-infection-novel-fluid-intervention-and-prevention/" />
</article-meta>
</front>
<body>
<sec>
<title>Full Text</title>
<p>Numerous experimental studies demonstrated that Pyruvate is more beneficial than anions in current fluids due to its beneficial biological and pharmacological properties via increasing hypoxia/anoxia tolerance, correcting hypoxic lactic acidosis and exerting anti-oxidative stress, which target against major features of pathological defects in Covid-19 viral infection: hypoxia and cytokine storm. These characteristics indicate that pyruvate is robustly systemic metabolism and multiorgan function protective in critical care patients with or without Covid-19 viral infection. Albeit it is not an anti-virus agent, studies suggest that pyruvate potentially facilitate anti-virus drugs, cytokine IL-6 blockers and interferons against Covid-19 and even inhibit virus replication as chloroquine treated Covid-19. Despite of not FDA-approved, many pyruvate clinical studies with several hundred patients subjected to various diseases strongly support its clinical effectiveness and safety. Currently, pyruvate is a nutritional supplement in markets. It is proposed in this review that compassionate uses of pyruvate-enriched intravenous and oral rehydration solutions are encouraged in intervention and prophylaxis of Covid-19 viral infection.</p>
</sec>
</body>
</article>